Danaher DHR Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Sales by Business | |||||
| Biotechnology | $7.29B+7.9% | $6.76B-5.8% | $7.17B-18.1% | $8.76B+2.2% | |
| Diagnostics | $9.94B+1.6% | $9.79B+2.2% | $9.58B— | —— | |
| Life Sciences | $7.33B+0.1% | $7.33B+2.6% | $7.14B— | —— | |
| Segment Reporting, Other Segment Item, Amount by Business | |||||
| Biotechnology | $4.29B+5.7% | $4.06B-2.9% | $4.18B-11.9% | $4.75B— | |
| Diagnostics | $6.68B+2.2% | $6.53B-0.6% | $6.57B-3.7% | $6.82B— | |
| Life Sciences | $5.58B+1.7% | $5.49B+2.1% | $5.37B+5.6% | $5.09B— | |
| Operating Income (Loss) by Business | |||||
| Biotechnology | $1.86B+10.6% | $1.69B-11.7% | $1.91B— | —— | |
| Diagnostics | $2.65B+1.0% | $2.63B+9.1% | $2.41B— | —— | |
| Life Sciences | $520M-40.8% | $879M-27.3% | $1.21B— | —— | |
| Identifiable assets by Business | |||||
| Biotechnology | $148.32B— | —— | —— | —— | |
| Depreciation by Business | |||||
| Biotechnology | $149M-1.3% | $151M-6.8% | $162M— | —— | |
| Diagnostics | $407M+3.3% | $394M+4.0% | $379M— | —— | |
| Life Sciences | $185M+10.8% | $167M+29.5% | $129M— | —— | |
| Capital expenditures, gross by Business | |||||
| Biotechnology | $370M-17.2% | $447M+7.2% | $417M+3.0% | $405M+5.2% | |
| Diagnostics | $592M+7.6% | $550M+0.7% | $546M— | —— | |
| Life Sciences | $186M-52.4% | $391M+22.2% | $320M— | —— | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | |||||
| Diagnostics | $227M+246% | -$155M-543% | $35M— | —— | |
| Life Sciences | $542M+374% | -$198M-488% | $51M— | —— | |
| Intangible Amortization by Business | |||||
| Biotechnology | $902M+4.5% | $863M-0.1% | $864M+6.4% | $812M— | |
| Diagnostics | $191M-0.5% | $192M-3.0% | $198M-2.5% | $203M— | |
| Life Sciences | $604M+4.9% | $576M+34.3% | $429M+2.4% | $419M— | |
| Goodwill by Business | |||||
| Biotechnology | $91.91B+4.8% | $87.74B-0.5% | $88.21B— | —— | |
| Diagnostics | $27.76B+1.4% | $27.37B-0.4% | $27.47B+0.1% | $27.44B-2.2% | |
| Life Sciences | $51.08B+3.8% | $49.21B+32.8% | $37.05B-62.4% | $98.62B-14.1% | |
| Sales by Product | |||||
| Nonrecurring revenue | $4.44B-1.5% | $4.51B-13.4% | $5.21B-9.7% | $5.77B+1.8% | |
| Recurring revenue | $20.13B+3.9% | $19.37B+3.7% | $18.68B-10.5% | $20.88B+9.1% | |
| Sales by Geography | |||||
| High-growth markets | $7.02B+2.2% | $6.87B-4.5% | $7.19B-6.7% | $7.71B-0.8% | |
| North America | $10.36B+0.6% | $10.3B+3.4% | $9.96B-15.1% | $11.73B+19.7% | |
| Other developed markets | $1.25B-0.1% | $1.25B-1.3% | $1.27B-5.6% | $1.35B-0.9% | |
| Western Europe | $5.94B+8.8% | $5.46B-0.2% | $5.47B-6.7% | $5.86B-0.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Danaher break its business down?
- Danaher (DHR) reports sales by business across 3 parts — Biotechnology, Diagnostics and Life Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Danaher's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Danaher's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
